Publication | Open Access
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
4.9K
Citations
47
References
2016
Year
In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke. (Funded by Edwards Lifesciences; PARTNER 2 ClinicalTrials.gov number, NCT01314313.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1